A year ago, i was evaluating the PEG technology ...
1. Clinical validation of Nektar's technology platform with small molecules
- Achieved first oral bioaviailability with a polymer conjugated drug
- Demostrated Nektar technology can modulate crossing of the blood-brain barrier
- Showed platform can greatly improve PK profile of anti-cancer agents to enhance efficacy and reduce side effects
2. Groundbreaking agreement signed with AstraZeneca
- Highlights value of Nektar's technology platform
- $1.5 B in milestones with significant double-digit royalities
3. Entered 2010 with $396 M in cash at end-2009
- Net positive cash flow of $20 M in 2009
- $31 M received in Q4 for license option extension
4. Proven technology platform (PEGylation will extend the "shelve-life" of drugs ... there's a company in Japan, Yushi Seihin is well-known for this technology ... )
5. Diverse R&D pipline
- Multiple therapeutic areas including high-value opportunities in pain and oncology
- NKTR-118 is the first successful PEGylation of oral small molecule; significant oral bioavailability with a PEGylated drug and demostrated the platform can modulate drug penetration into the CNS
- NKTR-102 for Ovarian Cancer, Breast Cancer in Phase 2
- NKTR-105 in cancer (myelosuppression) in Phase 1
6. Multiple high-value partnerships in place for late-stage products
- Partner with AstraZeneca to commercialise both NKTR-118 and NKTR-119 programs which includes $125 M cash upfront to Nektar
- NKTR-188 for opioid-induced constipation ($235 M in development milestones, $375 M in sales milestones, double-digit royalities)
- NKTR-119 for pain relief without OIC ($75 M in development milestone, $310 M in sales milestones, double-digit royalities)
- A total of up to 1.5 B in milestones in addition to royalities ... ... (ok if they don't spend more to develop their technologies ... )
No entry yet, will wait and monitor ...